Breaking News Instant updates and real-time market news.

2016-10-13 11:04:49

MDT

Medtronic

$82.97

-0.71 (-0.85%)

11:04

10/13/16

10/13

11:04

10/13/16

11:04

Medtronic cardiac devices gain FDA approval

Medtronic is the first company to receive FDA approval for its suite of cardiac rhythm and heart failure devices and leads to be scanned in both 3 and 1.5 Tesla MRI machines. This advancement gives patients with Medtronic SureScan MR-conditional pacemakers, implantable cardioverter-defibrillators and cardiac resynchronization therapy-defibrillators and leads access to MRI scans on any part of the body.

Cowen analyst Doug Schenkel noted that Abbott (ABT) announced yesterday it had received FDA approval for the professional version of its FreeStyle Libre glucose monitoring product and filed the consumer version of Libre, while Medtronic (MDT) also announced FDA approval of its 670G Hybrid Closed Loop system. Schenkel said Abbott's consumer Libre filing comes a few months ahead of his expectations but that Medtronic's timing was in-line with expectations. The analyst said the competitor announcements, which had been expected, do not change his views on DexCom (DXCM), Insulet (PODD), or Tandem Diabetes (TNDM) and he keeps Outperform ratings on all three of those stocks.

Wedbush analyst Tao Levy analyzed the recently released Summary and Effectiveness Data for Medtronic's (MDT) 670G System, which he does not believe many outside of the Continuous glucose monitoring, or CGM, manufacturers have read, and came away with the belief that its new Guardian Sensor CGM standalone system suffers from a relatively large rate of false hypoglycemia alarms. While it cannot be known for sure how competitive the Guardian Sensor will be when it is eventually approved and launched in the next several months, Levy thinks elevated false alarm rates could temper adoption and that it is "too early to assume" that the product will hinder Dexcom's (DXCM) growth. The analyst keeps a Neutral rating on Medtronic and an Outperform rating on Dexcom.

09/29/16

BARD

09/29/16NO CHANGEBARD

Dexcom, Insulet could be weighed down by competitive concerns, says Baird

Baird analyst Jeff Johnson said that while the FDA approvals announced yesterday for Abbott's (ABT) FreeStyle Libre Pro and Medtronic's (MDT) 670G were largely anticipated, he believes that both approvals came sooner than most expected, as did news that Abbott also recently filed for FDA approval of its consumer Libre system. The approvals could "change the narrative" in diabetes and could weigh on others in the sector in the near-term, most notably Dexcom (DXCM) and Insulet (PODD), Johnson tells investors. He keeps Neutral ratings on both and maintains an Overweight rating on Tandem Diabetes (TNDM), citing valuation for the difference.

08/26/16

PIPR

08/26/16NO CHANGEPIPR

Medtronic guidance conservative, says Piper Jaffray

After Medtronic reported higher than expected Q1 EPS and in-line revenue, Piper Jaffray analyst Brooks West says the quarter was "just fine." He says that the company's failure to raise its revenue guidance to reflect recent acquisitions was conservative and "de-risks" its now "beatable" guidance. West expects new products to bolster the company's revenue, and he predicts that it will continue to gain share in CRM. He keeps a $104 price target and Overweight rating on the stock.